| Drug ID: | Drug25 |
|---|
| Drug Name: | Mebendazole |
|---|
| CID: | 4030 |
|---|
| DrugBank ID: | DB00643 |
|---|
| Modality: | Small Molecule |
|---|
| Groups: | approved |
|---|
| US Approved: | YES |
|---|
| Other Approved: | YES |
|---|
| Identifier: |
NCT06335160
|
|---|
| Molecular Formula: | C16H13N3O3 |
|---|
| Molecular Weight: | 295.29 g/mol |
|---|
| Isomeric SMILES: | COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3 |
|---|
| Synonyms: | mebendazole; 31431-39-7; Pantelmin; Ovitelmin; Vermicidin; Vermirax; Mebenoazole; Mebutar; MBDZ; Besantin |
|---|
| Phase 0: | 0 |
|---|
| Phase 1: | 6 |
|---|
| Phase 2: | 5 |
|---|
| Phase 3: | 11 |
|---|
| Phase 4: | 10 |
|---|
| Description: | A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem] |
|---|
-
-
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
| dt228 |
4030 |
Mebendazole |
10383 |
TUBB4B
|
Homo sapiens (human) |
|
None |
| dt229 |
4030 |
Mebendazole |
1544 |
CYP1A2
|
Homo sapiens (human) |
|
None |
| dt230 |
4030 |
Mebendazole |
7846 |
TUBA1A
|
Homo sapiens (human) |
|
None |
| dt231 |
4030 |
Mebendazole |
203068 |
TUBB
|
Homo sapiens (human) |
|
None |
| dt232 |
4030 |
Mebendazole |
7846 |
TUBA1A
|
Homo sapiens (human) |
|
Inhibitor |
| dt233 |
4030 |
Mebendazole |
10383 |
TUBB4B
|
Homo sapiens (human) |
|
Inhibitor |
| dt234 |
4030 |
Mebendazole |
1543 |
CYP1A1
|
Homo sapiens (human) |
12841937 |
Inducer |
| dt235 |
4030 |
Mebendazole |
1576 |
CYP3A4
|
Homo sapiens (human) |
15096105 |
Substrate |
| dt236 |
4030 |
Mebendazole |
64816 |
CYP3A43
|
Homo sapiens (human) |
15096105 |
Substrate |
| dt237 |
4030 |
Mebendazole |
1577 |
CYP3A5
|
Homo sapiens (human) |
15096105 |
Substrate |
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
| NCT06335160 |
Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine |
None |
NOT_YET_RECRUITING |
Tanta University |
Ulcerative Colitis |
DRUG: Mebendazole |
Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
| No data available |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
| No data available |
PMID: 36040420
Year: 2022
Relationship Type:
Association
Score: 6.5
INTRODUCTION: According to the hygiene hypothesis, exposure to parasites may protect against inflammatory bowel disease (IBD). Our aim was to examine…
PMID: 35715495
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Mebendazole (MBZ) is an efficacious anthelmintic with known anti-inflammatory and fibrinolytic properties. In this study, we aimed to explore the pro…
